Market revenue in 2023 | USD 116.0 million |
Market revenue in 2030 | USD 167.0 million |
Growth rate | 5.3% (CAGR from 2023 to 2030) |
Largest segment | Infectious diseases |
Fastest growing segment | Oncology |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Oncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases |
Key market players worldwide | Roche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to point-of-care molecular diagnostics market will help companies and investors design strategic landscapes.
Infectious diseases was the largest segment with a revenue share of 93.45% in 2023. Horizon Databook has segmented the UK point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2018 to 2030.
Demand for innovative diagnostic and treatment products in the UK is expected to be higher owing to the rising prevalence of chronic diseases, the growing geriatric population, and the rising awareness levels of consumers. Though currently, molecular diagnostic services are not available in most parts of the country, initiatives taken by the National Health Services in training healthcare practitioners and funding for the same are expected to enhance the usage of PoC devices.
In addition, the application of molecular diagnostic tests in predicting and assessing the response of a drug and targeted drug delivery is expected to aid market growth during the forecast period. Government decisions regarding the privatization of the UK pathology and outsourcing are expected to change the market scenario during the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the UK point-of-care molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into UK point-of-care molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account